|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
|
EP1228766A1
(en)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
US8323645B2
(en)
*
|
2005-03-24 |
2012-12-04 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
AU2015201263B2
(en)
*
|
2005-12-30 |
2017-01-12 |
Amgen Inc. |
Material and methods for treating or preventing her-3 associated diseases
|
|
EP2097754B2
(en)
|
2006-11-28 |
2018-01-24 |
Daiichi Sankyo Europe GmbH |
Activated her3 as a marker for predicting therapeutic efficacy
|
|
KR101598229B1
(ko)
*
|
2007-02-16 |
2016-02-26 |
메리맥 파마슈티컬즈, 인크. |
Ｅｒｂｂ3에 대한 항체 및 이의 용도
|
|
CN101679974B
(zh)
|
2007-03-27 |
2015-09-30 |
航道生物技术有限责任公司 |
包含抗体替代轻链序列的构建体和文库
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2009151908A1
(en)
*
|
2008-05-25 |
2009-12-17 |
Wyeth |
Biomarkers for egfr/her/erbb drug efficacy
|
|
TW201006485A
(en)
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2138511A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
|
CN102149825B
(zh)
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
|
AU2013202400B2
(en)
*
|
2008-07-16 |
2014-10-09 |
Institute For Research In Biomedicine |
Human cytomegalovirus neutralizing antibodies and use thereof
|
|
WO2010019952A2
(en)
*
|
2008-08-15 |
2010-02-18 |
Merrimack Pharmaceuticals, Inc. |
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
|
|
WO2010051502A2
(en)
*
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
WO2010085845A1
(en)
*
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
JP5384672B2
(ja)
*
|
2009-02-24 |
2014-01-08 |
エフ．ホフマン−ラ ロシュ アーゲー |
癌のマーカーとしてのｓ−ＥｒｂＢ−３の使用
|
|
MY152068A
(en)
|
2009-03-20 |
2014-08-15 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
MX2011010166A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
|
EP2425009A4
(en)
|
2009-04-29 |
2013-01-23 |
Trellis Bioscience Llc |
Improved antibodies immunoreactive with heregulin-coupled her3
|
|
CA2761681A1
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
WO2011004899A1
(en)
*
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
AU2010303443A1
(en)
*
|
2009-10-09 |
2012-04-19 |
Merck Sharp & Dohme Corp. |
Generation, characterization and uses thereof of anti-Her 3 antibodies
|
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
|
SG10201407757XA
(en)
|
2009-10-23 |
2015-01-29 |
Millennium Pharm Inc |
Anti-gcc antibody molecules and related compositions and methods
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
ES2691717T3
(es)
|
2009-10-30 |
2018-11-28 |
Novartis Ag |
Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
|
|
EP2896632B1
(en)
*
|
2009-11-13 |
2017-10-25 |
Daiichi Sankyo Europe GmbH |
Material and methods for treating or preventing HER-3 associated diseases
|
|
MX2012006560A
(es)
|
2009-12-08 |
2012-10-05 |
Abbott Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
|
|
RS54795B1
(sr)
*
|
2009-12-22 |
2016-10-31 |
Roche Glycart Ag |
Anti-her3 antitela i njihova korišćenja
|
|
ES2602971T3
(es)
|
2010-03-02 |
2017-02-23 |
Kyowa Hakko Kirin Co., Ltd. |
Composición de anticuerpo modificado
|
|
KR101798679B1
(ko)
|
2010-03-11 |
2017-11-16 |
메리맥 파마슈티컬즈, 인크. |
３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
|
|
MX343227B
(es)
*
|
2010-04-09 |
2016-10-28 |
Aveo Pharmaceuticals Inc |
Anticuerpos anti-erbb3.
|
|
EP2571901B1
(en)
|
2010-05-20 |
2019-01-02 |
Ablynx N.V. |
Biological materials related to her3
|
|
PH12013500064A1
(en)
|
2010-07-09 |
2013-03-11 |
Exelixis Inc |
Combinations of kinase inhibitors for the treatment of cancer
|
|
CN107903321A
(zh)
|
2010-07-30 |
2018-04-13 |
诺华有限公司 |
纤连蛋白摇篮分子和其库
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2012019024A2
(en)
*
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
WO2012018404A2
(en)
*
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
|
AU2011290672B2
(en)
|
2010-08-20 |
2015-07-09 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
TW201302793A
(zh)
*
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
IT1402149B1
(it)
*
|
2010-10-04 |
2013-08-28 |
Ist Fisioterap Ospitalroma |
Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
|
|
CA2813796C
(en)
*
|
2010-10-18 |
2019-01-15 |
Mediapharma S.R.L. |
Erbb3 binding antibody
|
|
MX347981B
(es)
*
|
2010-11-01 |
2017-05-22 |
Symphogen As |
Composicion de anticuerpos pan-her.
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
ITRM20100577A1
(it)
*
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
EP2653540B9
(en)
|
2010-12-15 |
2018-05-16 |
Inter-University Research Institute Corporation Research Organization of Information and Systems |
Protein production method
|
|
CA2823337C
(en)
*
|
2010-12-29 |
2019-09-10 |
Expression Pathology, Inc. |
Her3 protein srm/mrm assay
|
|
US20140134170A1
(en)
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
MX2013010444A
(es)
|
2011-03-15 |
2014-03-21 |
Merrimack Pharmaceuticals Inc |
Superar la resistencia a inhibidores de la via erbb.
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
NO2707391T3
(https=)
*
|
2011-05-13 |
2018-04-07 |
|
|
|
JP2014516960A
(ja)
*
|
2011-05-19 |
2014-07-17 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） |
抗ヒトｈｅｒ３抗体及びその使用
|
|
JPWO2012176779A1
(ja)
|
2011-06-20 |
2015-02-23 |
協和発酵キリン株式会社 |
抗ｅｒｂＢ３抗体
|
|
EP2736928B1
(en)
*
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
PH12014500483A1
(en)
*
|
2011-09-30 |
2014-04-14 |
Regeneron Pharma |
Anti-erbb3 antibodies and uses thereof
|
|
JP6169085B2
(ja)
|
2011-10-06 |
2017-07-26 |
アベオ ファーマシューティカルズ， インコーポレイテッド |
抗ｅｒｂｂ３抗体に対する腫瘍応答の推定
|
|
JP2015504038A
(ja)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
低減した免疫原性を有するフィブロネクチン結合ドメイン
|
|
AU2012335543C1
(en)
|
2011-11-09 |
2017-12-14 |
Beijing Cotimes Biotech Co., Ltd., |
HER3 antibodies and uses thereof
|
|
DK2797957T3
(da)
|
2011-11-23 |
2019-09-23 |
Medimmune Llc |
Bindingsmolekyler specifikke for her3 og anvendelser deraf
|
|
CN104093742A
(zh)
*
|
2011-12-05 |
2014-10-08 |
诺华股份有限公司 |
抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体
|
|
EP3590538A1
(en)
*
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
CN104105709A
(zh)
*
|
2011-12-05 |
2014-10-15 |
诺华股份有限公司 |
抗her3的结构域ii的表皮生长因子受体3(her3)抗体
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
|
|
EP3369746A1
(en)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
ES2842201T3
(es)
*
|
2012-02-23 |
2021-07-13 |
Daiichi Sankyo Europe Gmbh |
Inhibidor de HER3 para modulación de radiosensibilidad
|
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
AU2013251312B2
(en)
|
2012-04-27 |
2018-03-22 |
Takeda Pharmaceutical Company Limited |
Anti-GCC antibody molecules and use of same to test for susceptibility to GCC-targeted therapy
|
|
WO2013164689A2
(en)
|
2012-05-02 |
2013-11-07 |
Lantto, Johan |
Humanized pan-her antibody compositions
|
|
AU2013322710A1
(en)
|
2012-09-25 |
2015-04-16 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
US9346890B2
(en)
*
|
2012-10-25 |
2016-05-24 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind ErbB3
|
|
TW202037609A
(zh)
|
2012-11-01 |
2020-10-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
|
AR093778A1
(es)
|
2012-11-08 |
2015-06-24 |
Hoffmann La Roche |
PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4
|
|
MA38165A1
(fr)
|
2012-11-08 |
2018-07-31 |
Hoffmann La Roche |
Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
HK1220465A1
(zh)
|
2013-03-06 |
2017-05-05 |
Merrimack Pharmaceuticals, Inc. |
抗c-met串联fc双特异性抗体
|
|
US9725520B2
(en)
*
|
2013-03-14 |
2017-08-08 |
The Board Of Regents Of The University Of Texas System |
HER3 specific monoclonal antibodies for diagnostic and therapeutic use
|
|
MX2015010854A
(es)
|
2013-03-14 |
2016-07-20 |
Genentech Inc |
Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
|
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3041863A4
(en)
|
2013-09-05 |
2017-08-16 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
US10519247B2
(en)
*
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
|
CN105849125B
(zh)
|
2013-11-07 |
2020-05-15 |
国家医疗保健研究所 |
神经调节蛋白变构抗her3抗体
|
|
EP3087394A2
(en)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
JP6632984B2
(ja)
|
2014-03-11 |
2020-01-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
抗ＥＧＦＲｖＩＩＩ抗体およびその使用
|
|
KR102445502B1
(ko)
|
2014-04-10 |
2022-09-21 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
WO2015157634A1
(en)
|
2014-04-11 |
2015-10-15 |
Kolltan Pharmaceuticals, Inc. |
Anti-erbb antibodies and methods of use thereof
|
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
|
MX2016014416A
(es)
|
2014-05-14 |
2017-02-23 |
Hoffmann La Roche |
Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
EP3268038B1
(en)
|
2015-03-09 |
2021-05-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CN116059395A
(zh)
|
2015-06-29 |
2023-05-05 |
第一三共株式会社 |
用于选择性制造抗体-药物缀合物的方法
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
US20220313841A1
(en)
*
|
2015-09-02 |
2022-10-06 |
Sanford Burnham Prebys Medical Discovery Institute |
Compositions and methods for treating nervous system injuries
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
AU2017235450A1
(en)
|
2016-03-15 |
2018-08-16 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
|
|
CA3017958C
(en)
|
2016-03-18 |
2024-03-12 |
Rutgers, The State University Of New Jersey |
Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
|
|
BR112019011564A2
(pt)
|
2016-12-09 |
2019-10-22 |
Seattle Genetics Inc |
anticorpos bivalentes mascarados por hélices superenroladas
|
|
US11273155B2
(en)
|
2016-12-12 |
2022-03-15 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
JP6679762B2
(ja)
|
2017-01-17 |
2020-04-15 |
第一三共株式会社 |
抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
|
|
CN117982673A
(zh)
|
2017-02-28 |
2024-05-07 |
第一三共株式会社 |
抗her3抗体-药物偶联物的应用
|
|
CA3056011A1
(en)
|
2017-03-14 |
2018-09-20 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
TW202532104A
(zh)
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
AU2018320470B2
(en)
|
2017-08-23 |
2025-04-24 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate preparation and lyophilization for same
|
|
CA3074208C
(en)
|
2017-08-31 |
2023-10-03 |
Daiichi Sankyo Company, Limited |
Novel method for producing antibody-drug conjugate
|
|
IL324591A
(en)
|
2017-08-31 |
2026-01-01 |
Daiichi Sankyo Co Ltd |
Improved antibody-drug conjugate production methods
|
|
WO2019165982A1
(en)
*
|
2018-02-28 |
2019-09-06 |
WuXi Biologics Ireland Limited |
Monoclonal antibody against human lag-3, method for preparing same, and use thereof
|
|
CN112512571B
(zh)
|
2018-03-22 |
2025-02-07 |
表面肿瘤学有限责任公司 |
抗il-27抗体及其用途
|
|
US12325737B2
(en)
|
2018-03-26 |
2025-06-10 |
Amgen Inc. |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
WO2019210144A1
(en)
*
|
2018-04-27 |
2019-10-31 |
Vanderbilt University |
Broadly neutralizing antibodies against hepatitis c virus
|
|
SG11202010496WA
(en)
|
2018-05-18 |
2020-12-30 |
Daiichi Sankyo Co Ltd |
Anti-muc1 antibody-drug conjugate
|
|
SG11202100653YA
(en)
|
2018-07-25 |
2021-02-25 |
Daiichi Sankyo Co Ltd |
Effective method for manufacturing antibody-drug conjugate
|
|
WO2020022475A1
(ja)
|
2018-07-27 |
2020-01-30 |
第一三共株式会社 |
抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
|
|
CA3108044A1
(en)
|
2018-07-31 |
2020-02-06 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
|
EA202190471A1
(ru)
|
2018-08-06 |
2021-05-24 |
Дайити Санкио Компани, Лимитед |
Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина
|
|
CN112739826A
(zh)
|
2018-08-23 |
2021-04-30 |
第一三共株式会社 |
抗体-药物缀合物的敏感性标志物
|
|
EA202190749A1
(ru)
|
2018-09-10 |
2021-07-09 |
Мирати Терапьютикс, Инк. |
Способы комбинированной терапии
|
|
WO2020059772A1
(ja)
|
2018-09-20 |
2020-03-26 |
第一三共株式会社 |
抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
|
|
CN111289748A
(zh)
*
|
2018-12-08 |
2020-06-16 |
惠州市中大惠亚医院 |
ErbB3蛋白在制备膀胱癌无创诊断产品中的应用
|
|
KR102905497B1
(ko)
|
2018-12-11 |
2025-12-30 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 parp 저해제의 조합
|
|
WO2020119719A1
(en)
*
|
2018-12-12 |
2020-06-18 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Anti-tim-3 antibodies and uses thereof
|
|
EP3894440A4
(en)
*
|
2018-12-13 |
2022-09-07 |
Surface Oncology, Inc. |
ANTI-IL-27 ANTIBODIES AND USES THEREOF
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
BR112022005583A2
(pt)
|
2019-09-26 |
2022-09-20 |
Amgen Inc |
Métodos para a produção de composições de anticorpos
|
|
IL292628A
(en)
|
2019-11-01 |
2022-07-01 |
Magenta Therapeutics Inc |
Anti-cd45 antibody and conjugates accordingly
|
|
JP2023511956A
(ja)
*
|
2020-01-24 |
2023-03-23 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
タンパク質－抗ウイルス化合物コンジュゲート
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
BR112022017924A2
(pt)
*
|
2020-03-10 |
2022-12-20 |
Massachusetts Inst Technology |
Composições e métodos para imunoterapia de câncer npm1c-positivo
|
|
CN111282165B
(zh)
*
|
2020-03-18 |
2025-03-21 |
核工业总医院 |
放射治疗定位显影液及定位显影标记敷贴
|
|
US20230273126A1
(en)
|
2020-06-04 |
2023-08-31 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
JP7847132B2
(ja)
|
2020-10-14 |
2026-04-16 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗ｈｅｒ３抗体と抗ｈｅｒ３抗体薬物複合体及びその医薬用途
|
|
KR20230087539A
(ko)
|
2020-10-15 |
2023-06-16 |
암젠 인크 |
항체 생산 방법에서의 상대적인 비결합 글리칸
|
|
WO2022109404A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Actinium Pharmaceuticals, Inc. |
Her3 radioimmunotherapy for the treatment of solid cancers
|
|
AU2021378152A1
(en)
|
2020-11-11 |
2023-06-22 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
|
|
US12551584B1
(en)
|
2020-12-07 |
2026-02-17 |
Actinium Pharmaceuticals, Inc. |
Lewis Y radioimmunotherapy for the treatment of cancer
|
|
US20240360436A1
(en)
|
2021-03-31 |
2024-10-31 |
DDBio. Co., Ltd. |
Vector and method for screening functional antigen-binding protein
|
|
TW202308700A
(zh)
|
2021-04-29 |
2023-03-01 |
大陸商上海匯連生物醫藥有限公司 |
抗體偶聯藥物的製備方法及應用
|
|
EP4352094A1
(en)
|
2021-06-07 |
2024-04-17 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
AU2022293634A1
(en)
*
|
2021-06-15 |
2024-01-18 |
Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
|
|
CN117881431A
(zh)
|
2021-08-24 |
2024-04-12 |
昆山新蕴达生物科技有限公司 |
一种由可断裂连接子偶联的抗体偶联药物
|
|
US20250076309A1
(en)
|
2021-10-05 |
2025-03-06 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
CN118401258A
(zh)
|
2021-12-09 |
2024-07-26 |
昆山新蕴达生物科技有限公司 |
一种亲和力改善的抗体-药物偶联物、其制备方法及应用
|
|
TW202341984A
(zh)
|
2022-01-28 |
2023-11-01 |
大陸商映恩生物製藥（蘇州）有限公司 |
Ｈｅｒ３抗體藥物偶聯物及其用途
|
|
WO2023165475A1
(zh)
*
|
2022-03-03 |
2023-09-07 |
四川科伦博泰生物医药股份有限公司 |
Her3结合蛋白及其用途
|
|
EP4514391A1
(en)
|
2022-04-27 |
2025-03-05 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
|
CN119212732A
(zh)
*
|
2022-04-29 |
2024-12-27 |
四川科伦博泰生物医药股份有限公司 |
抗体药物缀合物及其制备方法和用途
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
CN119403829A
(zh)
|
2022-05-11 |
2025-02-07 |
第一三共株式会社 |
对于肿瘤抗原特异性的抗体和cd47抑制剂的组合
|
|
AU2024218327A1
(en)
|
2023-02-09 |
2025-09-25 |
Beone Medicines I Gmbh |
Self-stabilizing linker conjugates
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
EP4721766A1
(en)
|
2023-06-02 |
2026-04-08 |
Daiichi Sankyo Company, Limited |
Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
|
|
CN116444672B
(zh)
|
2023-06-13 |
2023-11-03 |
上海偌妥生物科技有限公司 |
人表皮生长因子3的抗体、其制备方法及其应用
|
|
CN121568721A
(zh)
|
2023-06-29 |
2026-02-24 |
广州百济神州生物制药有限公司 |
生物活性缀合物、其制备方法和其用途
|
|
AR133125A1
(es)
|
2023-06-29 |
2025-08-27 |
Beigene Switzerland Gmbh |
Conjugados bioactivos, método de preparación y uso de estos
|
|
EP4737483A1
(en)
|
2023-06-30 |
2026-05-06 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate production method including purification step using activated carbon material
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
TW202540193A
(zh)
*
|
2024-03-14 |
2025-10-16 |
大陸商珠海普米斯生物科技有限公司 |
雙特異性抗體、抗體藥物偶聯物及其應用
|